Payment overview · 2025
General Payments
$674.37
38 reported records · 15 companies
Healthcare provider profile · identity verified
Joseph E Gerhardstein, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LEXINGTON, KY · NPI 1790780286
Verified facts
What the public records show
CMS Open Payments records show Joseph E Gerhardstein, M.D. received $674.37 in general payments during 2025 across 38 reported records.
PFIZER INC. accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Jardiance, Mounjaro, Ozempic, Paxlovid, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $141.30 | 20.9% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $114.17 | 16.9% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $89.64 | 13.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $74.19 | 11.0% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $50.01 | 7.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.69 | 5.4% | 2 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.11 | 3.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $23.52 | 3.5% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.67 | 3.1% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $18.29 | 2.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.27 | 2.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.50 | 2.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.10 | 2.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.90 | 2.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.01 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $661.95 | 37 |
| Education | $12.42 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $94.86 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $94.86 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $74.19 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $72.22 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $72.22 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $72.22 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $69.85 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $69.85 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $69.08 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $36.69 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $32.65 | 3 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $26.11 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.21 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 82 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 210 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 88 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 48 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 20 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
127 | 34 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
86 | 86 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
99 | 88 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
82 | 82 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
210 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1071 | 313 |
| Levothyroxine Sodium | Levothyroxine Sodium | 787 | 205 |
| Amlodipine Besylate | Amlodipine Besylate | 628 | 179 |
| Lisinopril | Lisinopril | 547 | 158 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 498 | 143 |
| Omeprazole | Omeprazole | 473 | 137 |
| Losartan Potassium | Losartan Potassium | 347 | 103 |
| Gabapentin | Gabapentin | 283 | 82 |
| Allopurinol | Allopurinol | 281 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 276 | 81 |
| Pravastatin Sodium | Pravastatin Sodium | 271 | 75 |
| Simvastatin | Simvastatin | 267 | 77 |
| Metformin Hcl | Metformin Hcl | 259 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 246 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 246 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 241 | 68 |
| Alendronate Sodium | Alendronate Sodium | 226 | 71 |
| Eliquis | Apixaban | 210 | 51 |
| Furosemide | Furosemide | 197 | 63 |
| Carvedilol | Carvedilol | 196 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 185 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 182 | 58 |
| Potassium Chloride | Potassium Chloride | 180 | 53 |
| Metformin Hcl Er | Metformin Hcl | 174 | 59 |
| Tramadol Hcl | Tramadol Hcl | 171 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 165 | 53 |
| Montelukast Sodium | Montelukast Sodium | 153 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 32 |
| Glimepiride | Glimepiride | 131 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 37 |
| Synthroid | Levothyroxine Sodium | 127 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 37 |
| Sertraline Hcl | Sertraline Hcl | 123 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 54 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 39 |
| Famotidine | Famotidine | 117 | 36 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 114 | 114 |
| Trazodone Hcl | Trazodone Hcl | 110 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 108 | 35 |
| Alprazolam | Alprazolam | 106 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 45 |
| Prednisone | Prednisone | 99 | 60 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 99 | 88 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 26 |
| Finasteride | Finasteride | 96 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 95 | 30 |
| Spironolactone | Spironolactone | 95 | 33 |
| Meloxicam | Meloxicam | 93 | 37 |
| Donepezil Hcl | Donepezil Hcl | 92 | 23 |
| Jardiance | Empagliflozin | 88 | 17 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 86 | 86 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 85 | 30 |
| Farxiga | Dapagliflozin Propanediol | 84 | 16 |
| Ozempic | Semaglutide | 84 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 38 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 82 | 82 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 22 |
| Clonazepam | Clonazepam | 80 | 15 |
| Valsartan | Valsartan | 74 | 20 |
| Chlorthalidone | Chlorthalidone | 73 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 17 |
| Atenolol | Atenolol | 72 | 18 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 70 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 67 | 21 |
| Ezetimibe | Ezetimibe | 67 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 16 |
| Memantine Hcl | Memantine Hcl | 67 | 17 |
| Buspirone Hcl | Buspirone Hcl | 66 | 20 |
| Trulicity | Dulaglutide | 66 | 13 |
| Baclofen | Baclofen | 65 | 28 |
| Celecoxib | Celecoxib | 65 | 20 |
| Ramipril | Ramipril | 65 | 18 |
| Bupropion Xl | Bupropion Hcl | 64 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 62 | 17 |
| Nifedipine Er | Nifedipine | 62 | 14 |
| Candesartan Cilexetil | Candesartan Cilexetil | 59 | 12 |
| Lansoprazole | Lansoprazole | 55 | 18 |
| Benazepril Hcl | Benazepril Hcl | 54 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 44 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 52 | 15 |
| Acyclovir | Acyclovir | 50 | 20 |
| Azithromycin | Azithromycin | 50 | 36 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 50 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 16 |
| Diazepam | Diazepam | 48 | 12 |
| Lorazepam | Lorazepam | 48 | 17 |
| Mounjaro | Tirzepatide | 48 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 46 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 46 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 46 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 24 |
| Irbesartan | Irbesartan | 42 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | 12 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Amoxicillin | Amoxicillin | 40 | 36 |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 39 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 11 |
| Cefdinir | Cefdinir | 38 | 32 |
| Mupirocin | Mupirocin | 37 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 14 |
| Lovastatin | Lovastatin | 36 | 11 |
| Mirtazapine | Mirtazapine | 36 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Klor-Con M20 | Potassium Chloride | 35 | 13 |
| Cephalexin | Cephalexin | 34 | 20 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | suppressed |
| Indapamide | Indapamide | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 14 |
| Ondansetron Odt | Ondansetron | 32 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 18 |
| Estradiol | Estradiol | 30 | 13 |
| Trimethoprim | Trimethoprim | 30 | suppressed |
| Nystatin | Nystatin | 29 | 16 |
| Promethazine Hcl | Promethazine Hcl | 29 | 11 |
| Fluconazole | Fluconazole | 28 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 28 | 11 |
| Bumetanide | Bumetanide | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 22 |
| Colchicine | Colchicine | 24 | 13 |
| Meclizine Hcl | Meclizine Hcl | 24 | 13 |
| Rybelsus | Semaglutide | 24 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Telmisartan | Telmisartan | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 17 |
| Dutasteride | Dutasteride | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Nadolol | Nadolol | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Yuvafem | Estradiol | 16 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Galantamine Er | Galantamine Hbr | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 13 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Famciclovir | Famciclovir | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Euthyrox | Levothyroxine Sodium | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $674.37 · 38 records | PFIZER INC. | ABRYSVO, BEXSERO, COMIRNATY, ELIQUIS, INJECTAFER, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, PEDIARIX, PREVNAR 20, PYRUKYND, REXULTI, Rybelsus, TZIELD, The Cologuard Plus Collection Kit, Tlando, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error